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ABSTRACT
Consideration of biomolecules in terms of their mo-
lecular building blocks provides valuable new infor-
mation regarding their synthesis, degradation and
similarity. Here, we present the FragmentStore, a
resource for the comparison of fragments found in
metabolites, drugs or toxic compounds. Starting
from 13 000 metabolites, 16 000 drugs and 2200
toxic compounds we generated 35 000 different
building blocks (fragments), which are not only
relevant to their biosynthesis and degradation but
also provide important information regarding side-
effects and toxicity. The FragmentStore provides a
variety of search options such as 2D structure, mo-
lecular weight, rotatable bonds, etc. Various
analysis tools have been implemented including
the calculation of amino acid preferences of frag-
ments’ binding sites, classification of fragments
based on the enzyme classification class of the
enzyme(s) they bind to and small molecule library
generation via a fragment-assembler tool. Using
the FragmentStore, it is now possible to identify
the common fragments of different classes of mol-
ecules and generate hypotheses about the effects of
such intersections. For instance, the co-occurrence
of fragments in different drugs may indicate
similar targets and possible off-target interactions
whereas the co-occurrence of fragments in a
drug and a toxic compound/metabolite could
be indicative of side-effects. The database is
publicly available at: http://bioinformatics.charite
.de/fragment_store.
INTRODUCTION
Across all kingdoms of life, biomolecules are formed from
molecular building blocks, suggesting that this principle
has been favoured during evolution. During metabolism,
the building block nature of biomolecules facilitates their
degradation into fragments. A systems biology view
of metabolism would benefit from considering these
fragments. For instance, a study investigating the set of me-
tabolites available to different organisms found that
common substructures were observed within the uniquely
used compounds in metabolic pathways, indicating
that there are metabolite-mediated relationships between
different organism groups (1).
During the past few decades, relatively few drugs have
reached the market due to high failure rates at the clinical
testing stage (2). The two main causes of these failures are
lack of efficacy and toxicity (3). In fact, one-third of po-
tential therapeutic compounds fail in clinical trials or are
removed from the market at a later stage due to unaccept-
able side-effects, often caused by the drug binding to an
off-target (4). Such drug polypharmacology has driven the
prediction and characterization of drug-target associ-
ations in order to identify possible side-effects of drugs
and identify new opportunities for therapeutic interven-
tion (5–8). Fragment-based drug design is a well-
established approach that has led to the successful devel-
opment of novel leads for many different targets (9).
However, fragment-based approaches can also be
employed to perform small molecule building-block
analyses for the identification of fragments responsible
for off-target binding and side-effects (10). The
Biochemical Substructure Search Catalogue (BiSSCat)
stores computationally constructed substructures of com-
pounds and can be used to determine possible additional
substrates for enzymes (11). Identification of fragments
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that have a role in toxicity, side-effects or that mediate
off-target interactions would aid the development of
safe and effective medical drugs. Furthermore, such
analyses could help to improve future toxicity testing in
line with the US National Academy of Sciences’ recom-
mendations to increase efficiency and decrease animal
usage (12).
Comparison of the fragments present in different classes
of small molecules such as metabolites, toxic compounds
and drugs facilitates the answering of questions such
as: (i) how many common fragments are there in the
different classes of molecules? (ii) How does the
synthesis and/or degradation of metabolites depend on
their fragment composition? (iii) Do those molecules
containing toxic fragments cause more side-effects?
(iv) Can knowledge about common fragments in
small molecules help optimize drug polypharmacology?
(v) Can side-effects of drugs be rationalized through
the identification of common fragments with metabolites?
To help researchers answer such questions we
developed the FragmentStore database which consists
of more than 35 000 fragments and property data such
as physicochemical information and binding site
preferences.
THE DATABASE
The FragmentStore database consists of more than 35 000
different fragments resulting from fragmentation of more
than 13 000 metabolic compounds, 2200 toxic compounds
and 16 000 drugs and pharmacologically characterized
compounds using two different fragmentation strategies:
(i) the compounds were recursively fragmented according
to the recap-rules and (ii) chains between ring structures
were cut out.
For completeness, the compounds were also recursively
fragmented according to their rotatable bonds, which
alone resulted in more than 150 000 fragments.
Properties such as molecular weight, logP and hydropho-
bicity are stored for all fragments. Furthermore, binding
site preferences were determined for each fragment using
all structures in the Protein Data Bank (PDB) (13) bound
to a ligand of which the fragment is part of (if at least one
crystallized structure is available in the PDB). These
binding site preferences are calculated based on the fre-
quency of amino acid types binding a fragment compared
to the amino acid frequencies for the entire protein
surface. The amino acid binding site preferences for each
fragment are displayed in a histogram with one bar for
each amino acid, thus allowing users to ascertain whether
there are particular patterns of amino acids responsible for
binding particular fragments. Moreover, identical frag-
ments in different binding sites are superimposed and
shown with the amino acids that form the binding
pocket. These superimpositions provide detailed informa-
tion about the mechanism of fragment binding and
provide valuable information about the specificity of inter-
action in both homologous and non-homologous proteins.
FragmentStore offers various ways of searching the
database:
. Fragments can be selected according to the rule used
for fragmentation, based on their chemical properties
or class.
. It is also possible to search for fragments with a
specific binding site amino acid or physicochemical
composition.
. An enzyme classification (EC) tree can be browsed and
fragments which bind to a particular class of enzymes
can be selected.
. A SCOP (14) classification tree can be browsed and
fragments which bind to a particular SCOP class of
proteins can be selected.
. Structural searches can be performed by uploading or
drawing a molecule.
. Property searches e.g. molecular weight, number of
atoms etc. can be carried out.
. Fragments can be searched using compound names
(excluding those obtained from commercial databases).
. A search box is available, called Fraggle, which allows
users to enter text for searching against drug names
and PDB header entries.
We have also implemented a fragment-assembler tool,
which allows users to build a library of small molecules




More than 35 000 fragments were generated by fragment-
ing three different compound libraries comprising metab-
olites, toxic molecules and drugs. More than 13 000
KEGG-metabolites (15) were fragmented for the metab-
olite dataset and more than 2200 compounds from the
SuperToxic database (16) were fragmented for the toxic
dataset.
Altogether, the drug dataset consists of fragments from
more than 16 000 unique drugs from the following re-
sources: SuperDrug (2400 drugs) (16), KEGG-drugs
(7000) (15,17), DrugBank’s approved drugs (1300)
(18), WDI drugs (Derwent World Drug Index) (7000)
and CMC drugs (MDL) (8000). For the last two data-
bases, we consider only drugs, which are publicly avail-
able, e.g. in PubChem. The fragments have direct links to
the compounds of SuperDrug, KEGG-drugs, DrugBank,
SuperToxic and KEGG-metabolites.
Fragmentation methods
The ligands in the above-mentioned datasets were frag-
mented using three different strategies. For the first
strategy, the compounds were fragmented recursively
using the recap-rules (19). The recap methodology helps
to identify fragments which are useful for combinatorial
chemistry. This fragmentation method allows libraries to
be generated which contain fragments that can be easily
connected by bonds that are easy to synthesize e.g. ester
bonds. Altogether, the recap-rules comprise eleven differ-
ent bonds: amide, ester, amine, urea, ether, olefin, quater-
nary nitrogen, bond between aromatic nitrogen and
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carbon, lactam-nitrogen and carbon, bonds between
aromatic rings and sulphonamide.
For the second strategy, chains between two ring struc-
tures are cut out. Due to its non-redundancy, this
fragment library is more suitable for statistical analysis
than libraries generated using recursive methods. For the
third strategy, the ligands were recursively fragmented by
their rotatable bonds. The latter fragmentation rule
produced the most fragments (see Figure 1).
To validate the fragments for inclusion into
FragmentStore, a modification of the Lipinski rule-of-five
was used. Astex Technology’s rule-of-three is useful for
constructing fragment libraries that are efficient for lead
generation (20). The rule-of-three criteria for
fragments (which can later be combined into compounds)
are that they should have a molecular weight no
more than 300 g/mol and that the number of hydrogen
bond donors, the number of hydrogen acceptors and the
clogP-value should not be more than three. Additionally,
two properties should also be considered during the selec-
tion of fragments for building the fragment library: the
number of rotatable bonds has to be less than four and
the polar surface area has to be at most 60. For inclusion
into the FragmentStore database, the fragments are only
allowed to break one of these rules. Furthermore, every
fragment in the FragmentStore consists of at least three
heavy atoms.
Calculation of the binding site properties
After fragmentation, the binding site preferences for the
fragments were calculated for all fragments which are
co-crystallized in the Protein Data Bank. For each
amino acid, the frequency of occurrence is calculated at
the fragment’s binding site and compared to the frequency
of occurrence at the protein’s surface. The binding site of a
fragment is defined as all amino acids within 5 A˚ of the
fragment. FragmentStore provides these binding site pref-
erences as bar charts. The fragments which were
Figure 1. Three methods of fragmentation. The figure shows only the fragments which break no more than one of the rules of the rule-of-three. In
the top panel, a compound is fragmented according to the linker rule, producing two fragments. The middle panel shows the same compound being
fragmented according to the recap-rules, producing a total of four fragments. Here, two other generated fragments were excluded because they broke
more than one rule (fragments not shown). The bottom panel shows the same compound being fragmented according to its rotatable bonds,
producing a total of 39 fragments (only a subset is shown for clarity). Thirteen other fragments were excluded using the rule-of-three.
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co-crystallized in more than one different protein structure
were superimposed using the superimposition function of
PyMOL (21). The superimposed fragments and its binding
sites are visualized using Jmol.
Fragment-assembler
We have also implemented a fragment-assembler tool,
which allows users to build a library of small molecules
based on the selection of fragments of their choice using
reverse recap-rules. The user is allowed to choose up to
three fragments, which are combined to make new com-
pounds that satisfy Lipinski’s rule-of-five (22). This rule
defines properties, which compounds should fulfil to
become drug candidates. This rule claims that an orally
available drug has no more than five hydrogen bond
donors, no more than ten hydrogen bond acceptors, a
molecular weight of <500 g/mol and the LogP-value,
which gives information about the lipophilicity of a
molecule and is defined as the logarithm of the
1-octanol/water partition, should be below five.
As fragment assembly is computationally expensive, the
user is sent the results (in SMILES format) by email
within 20min. The FragmentStore also provides an
example set of fragments that can be used to demonstrate
the capabilities of the fragment-assembler.
Structural fingerprint and similarity search
In order to search for fragments using structural features,
bit vector ‘structural fingerprints’, which encode chemical
and topological characteristics of a molecule, were
included. The structural fingerprint was implemented
using Open Babel (http://openbabel.sourceforge.net/),
which offers four different fingerprints (FP2, FP3, FP4,
MACCS).
Fingerprint 2 (http://openbabel.org/wiki/FP2) is widely
used for the comparison of small molecules and is path-
based and indexes linear fragments up to seven atoms.
However, this fingerprint is not optimal for the com-
parison of small fragments. To provide an optimal com-
parison of small fragments, a combination of fingerprint 2
and 4 (FP2, FP4) was used. Fingerprint 4 (http://
openbabel.org/wiki/FP4) is based on a set of SMARTS
patterns and also considers functional groups. The
combined fingerprint shows the best results in comparing
fragments.
This combined structural fingerprint is pre-calculated
for all fragments in the database and will be calculated
for the query fragments to compare it to the entries of
FragmentStore. For the similarity search the Tanimoto
coefficient is used, which gives values in the range of
zero (no bits in common) to unity (all bits the same).
Server
FragmentStore is designed as a relational database on a
MySQL server. Additionally, the MyChem package
(http://mychem.sourceforge.net/) is installed to provide a
complete set of functions for handling chemical data
within MySQL. Most of the functions used by MyChem
depend upon Open Babel. The structural fingerprint is
implemented in Open Babel 2.2.3 (http://openbabel
.sourceforge.net/). To allow the upload or drawing of a
query structure, the Marvin Sketch plugin (http://www
.chemaxon.com) was installed. For the visualisation
of the 3D structures Jmol (http://www.jmol.org/) was
installed. The website is built with php and web access is
enabled via Apache HTTP Server 2.2.
EXAMPLE OF USE
If one wants to find a ligand for a specific binding site of a
target, the first step could be the characterisation of the
pocket. Afterwards, fragments for the specific binding site
can be detected in FragmentStore. If, for example, one
part of the binding site consists of many hydrophobic
amino acids like methionine, the user is able to search
the FragmentStore database for fragments which have
hydrophobic binding site preferences. Beside the
fragment and its physicochemical properties, the user
gets the binding site preference as a bar plot.
Furthermore, the binding sites in which the fragment
occurs are superimposed and displayed in 3D using Jmol
(Figure 2).
FIRST ANALYSIS
In the following analysis we consider the fragments which
are produced after fragmenting the SuperDrug drugs, the
KEGG-metabolites and the highly toxic compounds from
the SuperToxic database using the linker strategy. All
ligands common to the SuperDrug and SuperToxic
datasets were excluded from the latter dataset and
all ligands with e.g. a ‘R’- or ‘*’-atom were excluded
from the KEGG-metabolites. The intersection of the
three ligand and resulting fragment datasets are shown
in Figure 3. Only a small number of fragments
are shared between all three classes of molecules. These
fragments tend to be very small and are probably not
essential for the compound’s specificity. As one would
expect, there are proportionally less fragments shared
between the toxic and metabolite fragments in comparison
to those shared between the drugs and metabolite
fragments. Surprisingly, although the toxic and drug
datasets have no common compounds, the datasets
share many similar fragments. These may contribute to
the toxic effect of drugs and even side-effects. Figure 3
shows an example of a fragment which only occurs in
the toxic and drug dataset but not in the
KEGG-metabolites. The fragment is part of the
chemotherapeutic drug, Prednimustine (23) and of
several toxic compounds, e.g. 40-(di-200-chloroethylamino)-
4-hydroxy-3-methyldiphenylamine. The compound
40-(di-200-chloroethylamino)-4-hydroxy-3-methyldiphenyl-
amine was shown to have an LD50 value of 1.43mg/kg
(i.p.) in rat (24) and is therefore highly toxic.
CONCLUSION AND FUTURE DIRECTIONS
The FragmentStore provides data on fragments from
drugs, metabolites and toxic compounds. A fragmentation
method should consider synthetic rules and distinguish
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Figure 3. The intersection between metabolite, toxic and SuperDrug compounds compared to the intersection of their respective fragments after
linker fragmentation. Only a small proportion of fragments are shared between all three classes. Although the toxic and drug dataset have no
common compounds, the datasets share many similar fragments; these common fragments may contribute to drug toxicity and may even have a role
in side-effects of medications. One such fragment, which is found in both the toxic and drug fragment dataset is shown. This is part of the
chemotherapeutic drug, Prednimustine and of the toxic compound 40-(di-200-chloroethylamino)-4-hydroxy-3-methyldiphenylamine. mw: molecular
weight; hbd: hydrogen bond donors; hba: hydrogen bond acceptors; rb: rotateable bonds; psa: polar surface area.
Figure 2. The binding site search feature of the FragmentStore can be used to retrieve fragments according to the amino acid type or
physicochemical properties of the residues they bind to. (a) First, the user selects the particular amino acids that they are interested in. In this
case all fragments that are crystallized in a binding pocket containing methionine residues will be retrieved. The results returned include: (b) a 2D
structure of the fragment; (c) the binding site amino acid propensities; (d) a Jmol applet displaying the superimposed binding sites and (e) a key for
the different amino acids which can be switched on and off in the applet.
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between linkers and fragments. Co-occurrence of
fragments in different drugs may indicate similar (off–)
targets and the co-occurrence of fragments in drugs and
toxic compounds or metabolites could be indicative for
side effects.
The systematic (computational) synthesis of libraries
from three fragments, as provided by the
fragment-assembler in FragmentStore, leads on average
to 10 000 compounds, which would be reasonable to
sample the chemical space of a particular medical target.
A future goal of the FragmentStore is a mapping of all
fragments onto metabolic and signaling pathways, hope-
fully elucidating interrelations between fragments, drugs,
targets and therapeutic effects. For the mapping we will
consider subtle changes and stereochemistry between the
enzymatic steps of metabolic pathways. In a next step
in-depth analysis will be carried out regarding the com-
pounds acting on different receptors in the signaling
cascades. The result will be a distribution of fragments/
scaffolds over certain regions of regulation—such as par-
ticular kinases or neuronal receptors that might explain
effects like multi-specificity.
AVAILABILITY
The FragmentStore database is freely available under the
URL: http://bioinformatics.charite.de/fragment_store/
and will be updated regularly.
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